Ken Griffin Argenx Se Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Argenx Se stock. As of the latest transaction made, Citadel Advisors LLC holds 21,500 shares of ARGX stock, worth $13.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,500

Previous 31,900 32.6%

Holding current value

$13.7 Million

Previous $19.6 Million 35.14%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$571.0 - $671.75 $21.6 Million - $25.4 Million	37,834 Added 7.36%	551,939 $327 Million
Q4 2024 Feb 14, 2025	SELL	$520.52 - $638.33 $52.5 Million - $64.4 Million	-100,821 Reduced 16.4%	514,105 $316 Million
Q3 2024 Nov 14, 2024	SELL	$434.22 - $551.9 $16.6 Million - $21.1 Million	-38,164 Reduced 5.84%	614,926 $333 Million
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $193 Million - $244 Million	540,814 Added 481.68%	653,090 $281 Million
Q1 2024 May 15, 2024	SELL	$356.95 - $413.29 $27.2 Million - $31.4 Million	-76,083 Reduced 40.39%	112,276 $44.2 Million
Q4 2023 Feb 14, 2024	SELL	$338.91 - $506.01 $84 Million - $125 Million	-247,764 Reduced 56.81%	188,359 $71.7 Million
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $27.9 Million - $41.4 Million	75,535 Added 20.95%	436,123 $214 Million
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $120 Million - $141 Million	333,055 Added 1209.66%	360,588 $141 Million
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $31.9 Million - $38.6 Million	-95,564 Reduced 77.63%	27,533 $10.3 Million
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $31.4 Million - $36.9 Million	91,819 Added 293.56%	123,097 $46.6 Million
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $18.7 Million - $21.6 Million	-54,455 Reduced 63.52%	31,278 $11 Million
Q2 2022 Aug 15, 2022	BUY	$269.58 - $378.88 $15.5 Million - $21.7 Million	57,367 Added 202.24%	85,733 $32.5 Million
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $1.6 Million - $2.07 Million	5,865 Added 26.07%	28,366 $9.93 Million
Q3 2021 Nov 15, 2021	BUY	$295.0 - $350.58 $4.46 Million - $5.3 Million	15,128 Added 205.18%	22,501 $6.8 Million
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $12.1 Million - $15.1 Million	-47,048 Reduced 86.45%	7,373 $2.22 Million
Q1 2021 May 17, 2021	BUY	$268.3 - $380.31 $4.72 Million - $6.7 Million	17,608 Added 47.83%	54,421 $15 Million
Q4 2020 Feb 16, 2021	BUY	$248.13 - $308.36 $8.1 Million - $10.1 Million	32,648 Added 783.87%	36,813 $10.8 Million
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $4.75 Million - $6 Million	-22,018 Reduced 84.09%	4,165 $1.09 Million
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $2.18 Million - $3.98 Million	17,113 Added 188.68%	26,183 $5.9 Million
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $836,032 - $1.27 Million	-7,682 Reduced 45.86%	9,070 $1.2 Million
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $1.02 Million - $1.58 Million	-9,597 Reduced 36.42%	16,752 $2.69 Million
Q3 2019 Nov 14, 2019	BUY	$113.31 - $150.51 $1.28 Million - $1.7 Million	11,294 Added 75.02%	26,349 $3 Million
Q2 2019 Aug 14, 2019	BUY	$115.0 - $141.58 $771,880 - $950,284	6,712 Added 80.45%	15,055 $2.13 Million
Q1 2019 May 15, 2019	SELL	$98.85 - $134.59 $1.52 Million - $2.07 Million	-15,413 Reduced 64.88%	8,343 $0
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $6.54 Million - $11.2 Million	-102,427 Reduced 81.17%	23,756 $2.28 Million
Q3 2018 Nov 13, 2018	BUY	$75.5 - $96.63 $4.97 Million - $6.36 Million	65,768 Added 108.86%	126,183 $0
Q2 2018 Aug 10, 2018	SELL	$74.84 - $100.16 $3.55 Million - $4.75 Million	-47,381 Reduced 43.95%	60,415 $0
Q1 2018 May 11, 2018	BUY	$56.95 - $85.19 $6.14 Million - $9.18 Million	107,796 New	107,796 $8.67 Million

Others Institutions Holding ARGX

# of Institutions

498

Shares Held

28.6M

Call Options Held

331K

Put Options Held

226K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $35.3B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account